HeartBeam posts Q2 presentation outlining heart attack detection progress and initial commercial launch traction
BEAT•Commercial rollout shows early traction
Commercial rollout for the FDA-cleared arrhythmia product included multiple practice agreements, initial shipments, patient onboarding, and expectations for larger orders in Q3 2026.
Heart attack detection development advances
HeartBeam outlined progress toward expanding its ECG platform from arrhythmia assessment into heart attack detection, with an FDA pre-submission planned imminently.
ALIGN-ACS chest-pain pilot enrolled 134 emergency-department patients across two sites in Belgrade; full results are slated for presentation at TCT 2026.
HEADSTART-ACS, a 500-patient study backed by the Indonesian government, passed 50% enrollment in under three months, ahead of schedule.
Development update included a completed working prototype of a 12-lead ECG patch, with an ischemia-detection pilot launched in about 50 high-risk patients.
Related News
U.S. FDA Grants Accelerated Approval To Bristol Myers Squibb's First Celmod Therapy Zenbexus™, In Combination With Daratumumab And Hyaluronidase-Fihj And Dexamethasone (Zdd) For Patients With Multiple Myeloma, As Early As First Relapse
Nubank quarterly net profit beats estimates, topping $1 billion for first time
